IP Library › Granted Patent US 12,517,124
Granted Patent B2
US 12,517,124 · App. 16/620,155 · Granted Jan 6, 2026

Chimeric receptor for use in whole-cell sensors for detecting analytes of interest

Inventors: Jerome Bonnet (Montpellier, FR); Hung-Ju Chang (Montpellier, FR)
Assignees: INSERM (Institute National de la Sante et de la Recherche Medicale); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS)
G01N33/566C07K16/18G01N33/5308G01N33/54387G01N33/554G01N33/563G01N33/56911G01N33/6857G01N33/6872C07K2317/80C07K2319/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,517,124
App. No.
16/620,155
Granted
Jan 6, 2026
Kind
B2
Abstract

The present invention relates to chimeric receptors that can be used in whole-cell sensors for detecting analytes of interest. The inventors showed that the DNA binding domains and downstream gene expression can be activated via dimerization of an artificial dimerization composed of a single chain variable domain. They demonstrated for the first time that an artificial bacterial receptor using an antibody-like domain can be activated and produce a transcriptional output upon ligand-binding. In particular, the present invention relates to a chimeric receptor polypeptide comprising: i) a first DNA binding domain, ii) at least one binding domain selected from the group consisting of heavy chain variable domain, camelid VHHs, or antibody mimetics having specificity for an analyte, and iii) a linker between the DNA binding domain and the binding domain.

Claims (12)

1 . A chimeric receptor polypeptide comprising (i) a first DNA binding domain, wherein the first DNA binding domain consists of an amino acid sequence with at least 75% identity with SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 13, (ii) at least one binding domain having specificity for an analyte of interest, wherein the binding domain is a single domain antibody selected from the group consisting of a heavy chain variable domain and a camelid VHH, and (iii) a linker between the first DNA binding domain and the at least one binding domain, wherein the linker consists of an amino acid sequence with at least 90% identity with SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6.

2 . The chimeric receptor polypeptide of claim 1 further comprising a spacer inserted between the linker and the at least one binding domain.

3 . The chimeric receptor polypeptide of claim 2 wherein the spacer comprises the amino acid sequence DTRLPMS (SEQ ID NO:7) or GGGSG (SEQ ID NO:12).

4 . The chimeric receptor polypeptide of claim 1 , wherein the analyte of interest is a small molecule.

5 . A cell-free system comprising the chimeric receptor polypeptide of claim 1 .

6 . The cell-free system of claim 5 wherein the chimeric receptor polypeptide is embedded partially or completely in a solid support.

7 . The cell-free system of claim 6 wherein the solid support is a porous substrate.

8 . The cell-free system of claim 6 wherein the solid support is paper.

9 . The cell-free system of claim 6 wherein the solid support comprises several spatially distinct reaction regions where the cell-free system is confined.

10 . The cell-free system of claim 6 wherein the components are lyophilized on the solid support.

11 . The cell-free system of claim 5 further comprising a reporter gene.

12 . The cell-free system of claim 11 wherein the reporter gene encodes a fluorescent protein.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2023
From: BONNET, JEROME; CHANG, HUNG-JU
To: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE; UNIVERSITE DE MONTPELLIER; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Reel/Frame 064478/0578 →
Priority Claims (2)
EP 17305690 · Jun 8, 2017 · regional
EP 17306060 · Aug 9, 2017 · regional
Continuity (1)
Related Publication 20200096507A1 · Mar 26, 2020
References Cited (22)
US 6716589B2 · Johansson · 2004 [cited by examiner]
US 7052906B1 · Lawson · 2006 [cited by examiner]
US 20030049799A1 · Schwartz · 2003 [cited by examiner]
US 20050003367A1 · Whitney · 2005 [cited by examiner]
WO WO9923116A1 · 1999 [cited by examiner]
WO WO2012031109A2 · 2012 [cited by examiner]
WO 2012125652A2 · 2012 [cited by applicant]
WO 2013022739A1 · 2013 [cited by applicant]
WO WO2017070554A1 · 2017 [cited by examiner]
Zschiedrich et al. “Molecular mechanisms of two-component signal transduction”, Sep. 25, 2016, J Mol Biol, 428(19), p. 1-42. (Year: 2016). [cited by examiner]
Strauss and Keller, “Pharmacological Interference with Protein-Protein Interactions Mediated by Coiled-Coil Motifs” a chapter from “Protein-Protein Interactions as New Drug Targets”, 2008, Handbook of Experimental Pharm… [cited by examiner]
Makeyev et al. “Cell-free immunology: construction and in vitro expression of a PCR-based library encoding a single-chain antibody repertoire”, 1999, FEBS Letters, vol. 444, p. 177-180. (Year: 1999). [cited by examiner]
Trainor et al. “Ensemble Modeling and Intracellular Aggregation of an Engineered Immunoglobulin-Like Domain”, 2016, Journal of Molecular Biology, vol. 428, p. 1365-1374. (Year: 2016). [cited by examiner]
Wikipedia, “Monobody” article, accessed Oct. 4, 2022. Made of record as a supporting reference submitted with remarks Nov. 25, 2022. (Year: 2022). [cited by examiner]
Holt et al. “Domain antibodies: proteins for therapy”, Nov. 2003, TRENDS in Biotechnology, vol. 21 No. 11, p. 484-490. (Year: 2003). [cited by examiner]
Pardee et al. “Paper-based Synthetic Gene Networks”, Nov. 6, 2014, Cell, 159(4), p. 940-954. (Year: 2014). [cited by examiner]
Roybal et al. “Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors”, Oct. 6, 2016, Cell, vol. 167, p. 419-432. (Year: 2016). [cited by examiner]
Tang et al. “A Nanobody-Based System Using Fluorescent Proteins as Scaffolds for Cell-Specific Gene Manipulation”, Aug. 14, 2013 , Cell, vol. 154 Issue 4, p. 928-939. (Year: 2013). [cited by examiner]
Fominaya et al.; “Target Cell-Specific DNA Transfer Mediated by a Chimeric Multidomain Protein. Novel Non-Viral Gene Delivery System”; Journal of Biological Chemistry, vol. 271, No. 18, May 3, 1996, pp. 10560-10568. [cited by applicant]
Courbet et al.; “Detection of pathological biomarkers in human clinical samples via amplifying genetic switches and logic gates”; Science Translational Medicine, vol. 7, No. 289, May 27, 2015, p. 289ra83. [cited by applicant]
Lindner et al.; “Topology, Dimerization, and Stability of the Single-Span Membrane Protein CadC”; Journal of Molecular Biology, vol. 426, No. 16, Jun. 16, 2014, pp. 2942-2957. [cited by applicant]
Kotova et al.; “Two-Hybrid Dual Bait System”; Current Protocols in Molecular Biology, Apr. 1, 2009. [cited by applicant]